Market revenue in 2023 | USD 125.8 million |
Market revenue in 2030 | USD 478.8 million |
Growth rate | 21% (CAGR from 2023 to 2030) |
Largest segment | Surrogate endpoints |
Fastest growing segment | Predictive Biomarkers |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers, Surrogate Endpoints |
Key market players worldwide | Labcorp Holdings Inc, PAREXEL, Icon PLC, Charles River Laboratories International Inc, Proteome Sciences PLC, H U Group Holdings Inc, Wuxi AppTec Co Ltd, NorthEast BioLab, Celerion, GenScript ProBio |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biomarker clinical phase outsourcing services market will help companies and investors design strategic landscapes.
Surrogate endpoints was the largest segment with a revenue share of 55.72% in 2023. Horizon Databook has segmented the South Korea biomarker clinical phase outsourcing services market based on predictive biomarkers, prognostic biomarkers, safety biomarkers, surrogate endpoints covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea biomarker clinical phase outsourcing services market , including forecasts for subscribers. This country databook contains high-level insights into South Korea biomarker clinical phase outsourcing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account